Key Points
- USANA Health Sciences Director Gilbert Fuller sold 1,057 shares of stock at an average price of $21.48, totaling approximately $22,704.
- The company's shares are currently down 3.3%, with a 52-week trading range between $18.69 and $41.83.
- Analysts have recently downgraded USANA's stock ratings, with Zacks Research changing their rating from "hold" to a "strong sell" and setting a new average target price of $36.00.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert Fuller sold 1,057 shares of the business's stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $21.48, for a total transaction of $22,704.36. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
USANA Health Sciences Stock Down 3.3%
Shares of NYSE:USNA opened at $20.55 on Wednesday. USANA Health Sciences, Inc. has a fifty-two week low of $18.69 and a fifty-two week high of $41.83. The firm has a 50-day simple moving average of $26.35 and a 200 day simple moving average of $28.80. The company has a market cap of $375.51 million, a PE ratio of 23.35, a P/E/G ratio of 0.94 and a beta of 0.61.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. The business had revenue of $200.22 million for the quarter. USANA Health Sciences had a return on equity of 6.96% and a net margin of 1.86%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. As a group, research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently weighed in on USNA. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, October 11th. Zacks Research cut USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 21st. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of USANA Health Sciences in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $36.00.
Get Our Latest Report on USANA Health Sciences
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Pzena Investment Management LLC grew its position in USANA Health Sciences by 9.4% in the 2nd quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company's stock worth $36,583,000 after purchasing an additional 103,074 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of USANA Health Sciences by 9.2% in the 1st quarter. American Century Companies Inc. now owns 255,242 shares of the company's stock worth $6,884,000 after acquiring an additional 21,445 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of USANA Health Sciences by 46.2% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company's stock worth $5,084,000 after acquiring an additional 59,535 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of USANA Health Sciences by 23.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock worth $4,693,000 after acquiring an additional 33,141 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of USANA Health Sciences by 64.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company's stock worth $4,582,000 after acquiring an additional 58,921 shares during the period. Institutional investors own 54.25% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
